Breaking Finance News

Zacks Investment Research issued a report on PRA Health Sciences Inc (NASDAQ:PRAH), bumping up its stock price target to $65.00 earlier today

Zacks Investment Research upped the price target of PRA Health Sciences Inc (NASDAQ:PRAH) to $65.00 stating a potential upside of 0.14%.

Previously on Tuesday September 06, 2016, UBS released a statement about PRA Health Sciences Inc (NASDAQ:PRAH) increased the target price from $50.00 to $55.00. At the time, this indicated a possible upside of 0.09%.

Just yesterday PRA Health Sciences Inc (NASDAQ:PRAH) traded 0.83% higher at $56.81. PRA Health Sciences Inc’s 50-day moving average is $52.81 and its 200-day moving average is $47.35. The last stock price is up 20.78% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 181,937 shares of PRAH traded hands, down from an average trading volume of 509,843

Recent Performance Chart

PRA Health Sciences Inc (NASDAQ:PRAH)

PRA Health Sciences Inc has 52 week low of $33.00 and a 52 week high of $57.24 with a PE ratio of 49.05 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 7 brokerages have issued a ratings update on the company. The average stock price target is $52.79 with 5 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell.

General Information About PRA Health Sciences Inc (NASDAQ:PRAH)

PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company's integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The Company's service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *